



Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference

October 9, 2019

Company to Host Investor Event and Webcast on Sunday October 27, 2019 at 6:30p.m. ET

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the single agent dose-escalation portion of the ongoing Phase 1 study of AG-270 in patients with MTAP-deleted tumors and the pre-clinical translational research supporting combination strategies have been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26 – 30, 2019 in Boston. AG-270 is an investigational, first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor.

The schedule for the presentations is as follows:

Title: A Phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion

Oral Date & Time: Sunday, October 27, 2019, 11:50 a.m. – 12:20 p.m. ET

Oral Session: Spotlight on Proffered Papers 1

Oral Location: Level 3, Ballroom AB

Poster Date & Time: Monday, October 28, 2019, 12:30 p.m. – 4:00 p.m. ET

Poster Session: Poster Session B: New Molecular Targets

Poster Location: Level 2, Hall D

Abstract: B116

Presenter: Rebecca Suk Heist, M.D., Massachusetts General Hospital

Title: Mitotic defects induced by MAT2A inhibitors guides translational drug combination strategies with AG-270 and taxanes

Poster Date & Time: Monday, October 28, 2019, 12:30 p.m. – 4:00 p.m. ET

Poster Session: Poster Session B: New Molecular Targets

Poster Location: Level 2, Hall D

Abstract: B115

Presenter: Peter Kalev, Ph.D., Agios Pharmaceuticals

Conference Call Information

Agios will host an investor event on October 27, 2019 at 6:30 p.m. ET in Boston to review the AG-270 Phase 1 dose-escalation data and pre-clinical research. The event will be webcast live and can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com. The archived webcast will be available on the company's website beginning approximately two hours after the event.

About Agios

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

About Agios/Celgene Collaboration

AG-270 is part of our 2016 global research collaboration agreement with Celgene Corporation focused on metabolic immuno-oncology. Celgene has the option to participate in a worldwide 50/50 cost and profit share with Agios, under which Agios is eligible for up to \$169 million in clinical and regulatory milestone payments for the program.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of AG-270; Agios' plans regarding future data presentations; and the potential benefit of its strategic plans and focus. The words "anticipate," "expect," "intend," "potential," "milestone," "goal," "will," "on track," "upcoming," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborators is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. Moreover, there can be no guarantee that the two approved oncology precision medicines being commercialized by Agios and its collaborators will receive commercial acceptance. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios'

ability to maintain key collaborations; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor & Media Contact:

Holly Manning, 617-844-6630
Associate Director, Investor Relations
Holly.Manning@agios.com



Source: Agios Pharmaceuticals, Inc.